BNP Paribas Exane Issues Positive Forecast for Amphenol (NYSE:APH) Stock Price

Amphenol (NYSE:APH) had its price objective hoisted by investment analysts at BNP Paribas Exane from $110.00 to $115.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the electronics maker’s stock. BNP Paribas Exane‘s price target indicates a potential upside of 38.82% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Rothschild & Co Redburn raised their price target on shares of Amphenol from $172.00 to $197.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Weiss Ratings lowered shares of Amphenol from a “buy (a-)” rating to a “buy (b)” rating in a research note on Friday, October 23rd. Bank of America increased their target price on shares of Amphenol from $99.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Evercore set a $100.00 target price on shares of Amphenol in a research note on Wednesday. Finally, Royal Bank Of Canada set a $100.00 target price on shares of Amphenol in a research note on Monday. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.97.

Amphenol Stock Up 2.3%

NYSE:APH traded up $1.88 during trading hours on Thursday, hitting $82.84. 8,124,711 shares of the company’s stock traded hands, compared to its average volume of 17,071,643. The stock’s fifty day moving average price is $81.31 and its two-hundred day moving average price is $75.38. The firm has a market cap of $204.28 billion, a P/E ratio of 41.49, a P/E/G ratio of 1.00 and a beta of 1.23. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.41 and a current ratio of 1.89. Amphenol has a twelve month low of $59.01 and a twelve month high of $89.93.

Amphenol (NYSE:APH) last announced its quarterly earnings data on Wednesday, October 28th. The electronics maker reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.07. Amphenol had a return on equity of 39.87% and a net margin of 17.73%. The firm had revenue of $10.23 billion during the quarter, compared to analyst estimates of $9.49 billion. During the same period last year, the company posted $0.93 EPS. The business’s quarterly revenue was up 65.1% compared to the same quarter last year. On average, research analysts expect that Amphenol will post 2.67 earnings per share for the current fiscal year.

Amphenol announced that its Board of Directors has initiated a stock buyback plan on Wednesday, October 28th that permits the company to repurchase $4 billion in shares. This buyback authorization permits the electronics maker to buy up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Amphenol

In other Amphenol news, EVP Lance E. D’amico sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $81.00, for a total value of $8,099,500.00. Following the completion of the sale, the executive vice president directly owned 114,130 shares of the company’s stock, valued at $9,243,959.35. The trade was a 46.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Richard Norwitt sold 372,208 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $81.14, for a total transaction of $30,199,096.08. Following the transaction, the chief executive officer owned 1,728,354 shares in the company, valued at approximately $140,230,001.79. This trade represents a 17.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 2,098,608 shares of company stock worth $172,316,688. 1.42% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amphenol

Several institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LP raised its position in Amphenol by 3,010.0% in the second quarter. Corient Private Wealth LP now owns 16,437,431 shares of the electronics maker’s stock worth $2,898,248,000 after purchasing an additional 15,908,901 shares in the last quarter. State Street Corp raised its holdings in shares of Amphenol by 24.2% in the 2nd quarter. State Street Corp now owns 71,281,059 shares of the electronics maker’s stock worth $12,107,146,000 after buying an additional 13,884,641 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Amphenol in the 2nd quarter worth approximately $1,600,531,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Amphenol by 90.9% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,900,956 shares of the electronics maker’s stock worth $666,051,000 after buying an additional 3,761,224 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Amphenol by 101.6% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 3,720,515 shares of the electronics maker’s stock worth $313,497,000 after buying an additional 1,874,988 shares during the period. Institutional investors and hedge funds own 97.01% of the company’s stock.

Key Stories Impacting Amphenol

Here are the key news stories impacting Amphenol this week:

• Positive Sentiment: Q3 results exceeded expectations: Amphenol reported adjusted earnings of $0.80 per share versus the $0.73 consensus estimate, while revenue rose 65.1% year over year to $10.23 billion, above expectations of $9.49 billion. Growth was driven by IT datacom demand, acquisitions and broad-based organic expansion. Amphenol’s Q3 Earnings Beat Estimates, Revenues Rise Y/Y
• Positive Sentiment: AI demand supports the outlook: Management highlighted record orders and strong demand tied to artificial intelligence infrastructure, along with contributions from CommScope. These trends helped support a stronger 2026 outlook, offsetting weakness in communications networks. Amphenol Q3 Earnings Call Highlights AI Demand and Growth Outlook
• Positive Sentiment: Analysts raised targets: UBS lifted its price target from $105 to $111 and assigned a Buy rating, while Truist raised its target from $107.50 to $112 and maintained Buy. The revisions indicate continued confidence in Amphenol’s earnings growth and AI exposure. UBS Group recommendations
• Positive Sentiment: Share repurchase announced: Amphenol authorized a $4 billion buyback, allowing the company to repurchase up to 2% of outstanding shares. The program could support per-share earnings and signals management’s confidence in the business. Amphenol Board Approves $4 Billion Stock Repurchase Plan
• Neutral Sentiment: Amphenol agreed to acquire AdvancedPCB and Humanetics Sensors, expanding its connectivity and sensor businesses. The deals may add to long-term growth, but their financial impact and integration requirements remain uncertain. Amphenol to Acquire Humanetics Sensors
• Negative Sentiment: Dividend reduced: The quarterly dividend was set at $0.15 per share, down 40% from $0.25 previously. Although the buyback is supportive, the dividend reduction could concern income-focused investors.

About Amphenol

Amphenol Corporation (NYSE: APH) is a global manufacturer of electrical, electronic and fiber-optic connectors, interconnect systems and related products. Its portfolio includes cable assemblies, sensors, antennas, backplane systems, radio-frequency components and other specialized electronic hardware.

The company serves customers across a range of industries, including automotive, aerospace and defense, information technology and data communications, industrial, mobile networks, commercial aerospace, medical and other markets.